Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)

被引:3
作者
Gluck, S.
Lobo, C.
Reis, I.
Lopes, G.
Carmody, C.
Tukia, K.
Hurley, J.
Seo, P.
Silva, O.
Slingerland, J.
Welsh, C.
机构
[1] Univ Miami, Sylvester Canc Ctr, Miami, FL USA
[2] Florida Canc Specialists, Port Charlotte, FL USA
[3] Univ Miami, Braman Family Breast Canc Inst, Miami, FL USA
[4] Ctr Canc, Singapore, Singapore
关键词
D O I
10.1200/jco.2008.26.15_suppl.1089
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1089
引用
收藏
页数:1
相关论文
empty
未找到相关数据